Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Systems to Raise $7.7M in Private Placement

NEW YORK, Sept. 8 (GenomeWeb News) - Proteome Systems plans to raise approximately AU$10 million ($7.7 million) through a private placement to institutional and professional investors in the UK, US, and Australia, the Australian company said today.

 

In the placement, which still requires shareholder approval, Proteome Systems will issue up to 33.33 million fully paid ordinary shares to the investors at a price of AU$.30 per share.

 

The company expects net proceeds of approximately AU$9.75 million from the placement, allowing it to further develop its diagnostics and therapeutics business. In particular, Proteome Systems plans to accelerate the development of its diagnostic for active tuberculosis and to start clinical development of one of its lead scavenger drug compounds as a topical treatment for a range of dermatological diseases.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.